Recent Updates
Recently added Catalysts

Avidity Biosciences, Inc.

RNAMFDA catalysts, PDUFA dates & pipeline intelligence
$72.82
▲ +0.07 · +0.1%

Last traded Feb 26, 2026. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full RNAM financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $21.5152W HIGH $73.06
Volume
16.84 M
Value Traded
1.23 B
Short % Float
-
Days to Cover
1.7
-0.01%Week
+0.34%1 Month
+1.65%3 Month
+49.96%6 Month
+184.45%5 Year
+264.1%All Time

Cash Data

Unlock RNAM cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
11.30 B
EPS (TTM)
-4.96
P/E Ratio
-
Ent. Value
9.65 B
Total Shares
155.15 M
Float Shares
145.88 M
Insiders
5.98%
Institutions
92.11%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 topline data readout
delpacibart etedesiran (del-desiran)
myotonic dystrophy type 1 (DM1)
BreakthroughFast TrackOrphan
Phase 3RNA-Based TherapiesNervous System
Unlock every RNAM catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

RNAM Catalyst Timeline

Dated clinical, regulatory and corporate events for Avidity Biosciences, Inc.

Unlock the full RNAM catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How RNAM actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-06-30delpacibart braxlosiran (del-brax) Phase 1/2 topline data readout Phase 1/2
Unlock 1 more RNAM historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
AOC 1044 Small moleculeNCT07587242Muscular DystrophiesPhase 3 RECRUITING 70Jul 1, 2030
Unlock the RNAM pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every RNAM program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
del-zota Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44)Phase 1/22025-05-08statistically significant increases in exon skipping; substantial increase in dystrophin production; significant reduction in creatine kinase levels to near normalRead MoreAvidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE TM trial in thRead More
Scroll for more · summaries link to the source press release
Unlock every RNAM trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock RNAM insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Hughes Steven GeorgeOfficer (Chief Medical Officer)Sell -2,017 34,477 held$72.45 01/21/2026
Unlock the full RNAM insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in RNAM

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in RNAM for Q2 2026.
Unlock every fund holding RNAM
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in RNAM
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see RNAM ownership
Insider and institutional ownership, quarter by quarter.

RNAM Short Interest

Shares sold short, counted twice a month.

-
Short % of Float
of tradable shares sold short
9.0M
Shares Sold Short
1.7 Low
Days to Cover
trading days of normal volume to buy every short share back
5.4M
Avg Daily Volume
the average used for days to cover
Unlock RNAM short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock RNAM option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live RNAM option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock RNAM options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How RNAM ranks across every disease it competes in

Competitive Position is a premium feature
See how RNAM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

RNAM News

About Avidity Biosciences, Inc.

Founded2012
BIOPHARMAWATCH ELITE PLUS
Trade the next RNAM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime